ICON Public (ICLR) to Release Quarterly Earnings on Wednesday

ICON Public (NASDAQ:ICLR) is set to announce its earnings results after the market closes on Wednesday, April 24th. Analysts expect the company to announce earnings of $3.30 per share for the quarter. ICON Public has set its FY24 guidance at $14.50-$15.30 EPS.Investors interested in registering for the company’s conference call can do so using this link.

ICON Public (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.13. The business had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a net margin of 7.54% and a return on equity of 11.42%. On average, analysts expect ICON Public to post $14 EPS for the current fiscal year and $17 EPS for the next fiscal year.

ICON Public Price Performance

NASDAQ ICLR opened at $294.03 on Wednesday. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.40. The company has a fifty day simple moving average of $315.94 and a 200 day simple moving average of $280.08. The company has a market cap of $24.26 billion, a P/E ratio of 39.84, a P/E/G ratio of 1.45 and a beta of 1.15. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Chartwell Investment Partners LLC boosted its stake in shares of ICON Public by 23.5% in the 4th quarter. Chartwell Investment Partners LLC now owns 8,589 shares of the medical research company’s stock valued at $2,431,000 after purchasing an additional 1,636 shares during the last quarter. LM Advisors LLC bought a new position in ICON Public in the fourth quarter valued at approximately $26,000. Crossmark Global Holdings Inc. bought a new position in ICON Public in the fourth quarter valued at approximately $201,000. State of Tennessee Treasury Department lifted its stake in ICON Public by 2.4% in the second quarter. State of Tennessee Treasury Department now owns 110,747 shares of the medical research company’s stock valued at $27,709,000 after buying an additional 2,605 shares in the last quarter. Finally, SkyView Investment Advisors LLC raised its holdings in shares of ICON Public by 4.4% in the second quarter. SkyView Investment Advisors LLC now owns 2,505 shares of the medical research company’s stock valued at $627,000 after purchasing an additional 105 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on ICLR shares. Mizuho reaffirmed a “buy” rating and set a $346.00 price objective on shares of ICON Public in a report on Thursday, April 4th. Robert W. Baird increased their price target on shares of ICON Public from $345.00 to $362.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Evercore ISI increased their price target on shares of ICON Public from $325.00 to $350.00 and gave the company an “outperform” rating in a report on Friday, February 23rd. Barclays increased their target price on shares of ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. increased their target price on shares of ICON Public from $295.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 20th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $319.45.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.